The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development

    loading  Checking for direct PDF access through Ovid

Abstract

It is estimated that by 2030 nearly three-quarters of persons living with HIV will be 50 years and older. The aging HIV population presents a new clinical concern for HIV providers: adverse effects from polypharmacy. An aging population means more comorbidities and potentially more drug-drug interactions for providers to manage. This review discusses major comorbidities including cardiovascular disease, anticoagulation, hypertension, diabetes mellitus and malignancy and considerations for drug-interactions with antiretrovirals.

Related Topics

    loading  Loading Related Articles